BRPI0413430B8 - derivados de amida os um sal destes, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de doenças em que está implicado o herpesvírus. - Google Patents

derivados de amida os um sal destes, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de doenças em que está implicado o herpesvírus.

Info

Publication number
BRPI0413430B8
BRPI0413430B8 BRPI0413430A BRPI0413430A BRPI0413430B8 BR PI0413430 B8 BRPI0413430 B8 BR PI0413430B8 BR PI0413430 A BRPI0413430 A BR PI0413430A BR PI0413430 A BRPI0413430 A BR PI0413430A BR PI0413430 B8 BRPI0413430 B8 BR PI0413430B8
Authority
BR
Brazil
Prior art keywords
infection
caused
treatment
diseases
chickenpox
Prior art date
Application number
BRPI0413430A
Other languages
English (en)
Inventor
Kamikawa Akio
Suzuki Hiroshi
Miyata Junji
Sudo Kenji
Kawano Tomoaki
Kontani Toru
Hamaguchi Wataru
Original Assignee
Astellas Pharma Inc
Rational Drug Design Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Rational Drug Design Laboratories filed Critical Astellas Pharma Inc
Publication of BRPI0413430A publication Critical patent/BRPI0413430A/pt
Publication of BRPI0413430B1 publication Critical patent/BRPI0413430B1/pt
Publication of BRPI0413430B8 publication Critical patent/BRPI0413430B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

derivados de amida o objetivo consiste em se propor um composto inédito útil em medicamentos, especialmente em medicamentos para diversas doenças causadas por infecção com vírus que pretendem à família herpesviridae, isto é, na prevenção ou tratamento de infecções com diversos herpes-vírus, mais especificamente, varicela causada pela infecção com vírus zoster de varicela, her-pes zoster causado por infecção repetida com vírus zoster de varicela persistente, herpes labial, e encefalite herpética causada por infecção com hsv1, herpes genital causado por infecção com hsv-2 etc. um derivado de n-{2-[ (4-fenil substituído)amino]-2-oxoetil} tetraidro-2h-tiopiran-4-carboxamida tendo um substituinte heteroarila específico de 5 ou 6 membros na posição 4 tem uma atividade antiviral favorável e torna possível o tratamento das doenças acima por administração oral de uma pequena dose.
BRPI0413430A 2003-08-08 2004-08-05 derivados de amida os um sal destes, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de doenças em que está implicado o herpesvírus. BRPI0413430B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003290850 2003-08-08
JP2003-290850 2003-08-08
PCT/JP2004/011573 WO2005014559A1 (ja) 2003-08-08 2004-08-05 アミド誘導体

Publications (3)

Publication Number Publication Date
BRPI0413430A BRPI0413430A (pt) 2006-10-17
BRPI0413430B1 BRPI0413430B1 (pt) 2019-04-30
BRPI0413430B8 true BRPI0413430B8 (pt) 2021-05-25

Family

ID=34114142

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413430A BRPI0413430B8 (pt) 2003-08-08 2004-08-05 derivados de amida os um sal destes, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de doenças em que está implicado o herpesvírus.

Country Status (19)

Country Link
US (2) US7465748B2 (pt)
EP (1) EP1652843B1 (pt)
JP (1) JP4549974B2 (pt)
KR (1) KR101157074B1 (pt)
CN (1) CN100445271C (pt)
AU (1) AU2004263448B2 (pt)
BR (1) BRPI0413430B8 (pt)
CA (1) CA2535199C (pt)
CY (1) CY1115461T1 (pt)
DK (1) DK1652843T3 (pt)
ES (1) ES2462292T3 (pt)
MX (1) MXPA06001526A (pt)
NO (1) NO335467B1 (pt)
PL (1) PL1652843T3 (pt)
PT (1) PT1652843E (pt)
RU (1) RU2336273C2 (pt)
SI (1) SI1652843T1 (pt)
TW (1) TW200505894A (pt)
WO (1) WO2005014559A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0402309A3 (en) * 2001-12-21 2008-09-29 Novo Nordisk As Amide derivatives as glucokinase activators and pharmaceutical compositions containing them
PL215132B1 (pl) * 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
TW200505894A (en) * 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative
ES2399052T3 (es) 2004-01-06 2013-03-25 Novo Nordisk A/S Heteroaril-ureas y su uso como activadores de glucocinasa
JPWO2006082821A1 (ja) * 2005-02-02 2008-06-26 アステラス製薬株式会社 ヘルペスウイルスが関与する疾患の予防若しくは治療剤
DE602006013938D1 (de) * 2005-02-02 2010-06-10 Astellas Pharma Inc Wirkstoff zur prävention/behandlung von erkrankungen infolge von acyclovir-resistentem herpesvirus
DE602006016069D1 (de) * 2005-02-02 2010-09-23 Astellas Pharma Inc Therapeutischer wirkstoff zur behandlung von herpes progenitalis nach der entwicklung von läsionen
JP5011739B2 (ja) * 2005-02-03 2012-08-29 アステラス製薬株式会社 テトラヒドロ−２ｈ−チオピラン−４−カルボキサミド誘導体を含有する医薬組成物
JP2009500378A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
WO2007006760A1 (en) * 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
KR101446973B1 (ko) * 2005-07-14 2014-10-07 트랜스테크 파르마 엘엘씨 우레아 글루코키나제 활성제
WO2008084043A1 (en) * 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
CA2675111C (en) 2007-01-11 2016-04-05 Novo Nordisk A\S Urea glucokinase activators
DE102008014523A1 (de) * 2008-03-15 2009-09-17 Robert Bosch Gmbh Heizgerät
JP5381978B2 (ja) * 2008-04-02 2014-01-08 アステラス製薬株式会社 アミド誘導体含有医薬組成物
SI2565191T1 (sl) * 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
JPWO2010047295A1 (ja) 2008-10-20 2012-03-22 アステラス製薬株式会社 帯状疱疹関連痛の予防又は治療薬
CN108623577B (zh) * 2018-05-08 2020-09-25 山东百诺医药股份有限公司 阿莫奈韦及其中间体的制备方法
EP3806852A1 (en) 2018-06-12 2021-04-21 vTv Therapeutics LLC Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2020038812A1 (en) * 2018-08-20 2020-02-27 Rijksuniversiteit Groningen New process for the preparation of amenamevir
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE9800154A (et) * 1995-12-29 1998-12-15 Boehringer Ingelheim Pharmaceuticals, Inc. Herpesviirusevastaste omadustega fenüültiasoolderivaadid
US6288091B1 (en) * 1995-12-29 2001-09-11 Boehringer Ingelheim Ltd. Antiherpes virus compounds and methods for their preparation and use
AU3289299A (en) * 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
WO2000029399A1 (en) * 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
DE50008597D1 (de) * 1999-03-08 2004-12-16 Bayer Healthcare Ag Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
AU5283900A (en) * 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
WO2000071510A2 (en) * 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
CN1473157A (zh) * 2000-11-10 2004-02-04 ֮����ҩ��ʽ���� 酰胺衍生物
DE10139060A1 (de) 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate
WO2003095435A1 (fr) 2002-05-09 2003-11-20 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amides
TW200505894A (en) * 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative

Also Published As

Publication number Publication date
DK1652843T3 (da) 2014-05-05
NO335467B1 (no) 2014-12-15
RU2336273C2 (ru) 2008-10-20
KR20060073928A (ko) 2006-06-29
EP1652843B1 (en) 2014-04-02
TW200505894A (en) 2005-02-16
BRPI0413430B1 (pt) 2019-04-30
JP4549974B2 (ja) 2010-09-22
PL1652843T3 (pl) 2014-09-30
RU2006106922A (ru) 2006-08-27
CN1832930A (zh) 2006-09-13
CY1115461T1 (el) 2017-01-04
JPWO2005014559A1 (ja) 2006-10-05
CA2535199C (en) 2010-12-14
US7465748B2 (en) 2008-12-16
SI1652843T1 (sl) 2014-06-30
AU2004263448A1 (en) 2005-02-17
EP1652843A1 (en) 2006-05-03
NO20061100L (no) 2006-03-07
CA2535199A1 (en) 2005-02-17
US6903125B2 (en) 2005-06-07
MXPA06001526A (es) 2006-05-25
US20050032855A1 (en) 2005-02-10
KR101157074B1 (ko) 2012-06-22
AU2004263448B2 (en) 2009-02-05
ES2462292T3 (es) 2014-05-22
CN100445271C (zh) 2008-12-24
TWI341311B (pt) 2011-05-01
BRPI0413430A (pt) 2006-10-17
US20060229295A1 (en) 2006-10-12
EP1652843A4 (en) 2010-07-28
WO2005014559A1 (ja) 2005-02-17
PT1652843E (pt) 2014-06-02

Similar Documents

Publication Publication Date Title
BRPI0413430B8 (pt) derivados de amida os um sal destes, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de doenças em que está implicado o herpesvírus.
ES2602956T3 (es) Composiciones de antibiótico para tratamiento de conjuntivitis
Maudgal et al. Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir: A water-soluble ester of acyclovir
BR9910849A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido.
BR9810745A (pt) Derivados de benzimidazol
Smith et al. In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl) guanine (acycloguanosine)
JPS59130223A (ja) 相乗作用を示す抗ヘルペス組成物
ATE67180T1 (de) P-guanidinbenzoesaeurederivate und pharmazeutische mittel, die sie als aktiven inhaltsstoff enthalten.
ATE302197T1 (de) Amidderivate
CA1318850C (en) Pharmaceutical products
EP0590024A1 (en) Topical preparation for better healing of herpes injuries.
DK2374461T3 (en) Piroxicam for the prophylactic and therapeutic treatment of herpes infections
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
ATE236923T1 (de) Arabinosyladenin-derivative
EP0101441B1 (en) Anti-viral compositions
Connell et al. Synergistic activity of combinations of recombinant human alpha interferon and acyclovir, administered concomitantly and in sequence, against a lethal herpes simplex virus type 1 infection in mice
Power et al. Randomised double-blind trial of bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration.
Maudgal et al. Evaluation of bromovinyldeoxyuridine-related compounds in the treatment of experimental herpes simplex keratitis
Van Bijsterveld et al. Bromovinyldeoxyuridine and interferon treatment in ulcerative herpetic keratitis: a double masked study.
Nikkels et al. Current treatments of muco-cutaneous herpes simplex virus infections
Centifanto et al. 9-(2-hydroxyethoxymethyl) guanine as an inhibitor of herpes simplex virus replication.
EP1844776A4 (en) AGENT FOR THE PREVENTION / TREATMENT OF A DISEASE CAUSED BY A HERPES ACYCLOVIR-RESISTANT VIRUS
US5242946A (en) Treating herpes Viral infections
Upadhyay et al. The effect of HSV multiplication rate on antiviral drug efficacy in vitro
WO2016185069A1 (es) Una composición farmacéutica antiviral de uso tópico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: ASTELLAS PHARMA INC. (JP) , RATIONAL DRUG DESIGN L

B25A Requested transfer of rights approved

Owner name: ASTELLAS PHARMA INC. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF